WW International Beats Q4 Revenue Estimates by 8.7%, Clinical Subscriptions Up 32%
WW International reported Q4 revenue of $162.8 million, beating estimates by 8.7% and posting a $0.58 per-share loss versus a $2.03-share loss estimate, while adjusted EBITDA reached $18 million, up 49% year-over-year. The clinical subscription business grew 32% to $27 million, and GLP-1 integration drove 29% greater member weight loss.
1. Q4 Financial Results
WW reported Q4 revenue of $162.8 million, beating analyst expectations by 8.7% despite an 11.7% year-over-year decline, and narrowed its loss to $0.58 per share versus a forecasted $2.03 loss. Adjusted EBITDA rose to $18.04 million, surpassing the $12.11 million projection.
2. Clinical Subscription Growth
The clinical subscription business generated $27 million in Q4 revenue, up 32% year-over-year, driven by 130,000 active subscribers. Total end-of-period subscribers across all services reached 2.8 million, reflecting growing adoption of medically centric weight management offerings.
3. Strategic Repositioning and GLP-1 Integration
WW is integrating GLP-1 medications with its behavioral programs, and members in the GLP-1 Success Program lost 29% more body weight on average compared to medication alone. New Med+ member acquisitions increased, with 50% of new Med+ members being new to the brand, supporting its repositioning efforts.
4. Marketing Investment and Outlook
Marketing expenses rose to 40% of Q4 revenue as WW invests to raise awareness of new offerings, which could pressure margins if not managed carefully. For full-year 2026, WW guided revenue of $620–$635 million, adjusted EBITDA of $105–$115 million, and projected approximately 2.65 million total subscribers by Q1.